Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Penumbra Inc (PEN)

Penumbra Inc (PEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,308,442
  • Shares Outstanding, K 38,379
  • Annual Sales, $ 1,059 M
  • Annual Income, $ 90,950 K
  • EBIT $ 2 M
  • EBITDA $ 29 M
  • 60-Month Beta 0.51
  • Price/Sales 8.79
  • Price/Cash Flow 86.12
  • Price/Book 8.46

Options Overview Details

View History
  • Implied Volatility 43.39% ( -1.70%)
  • Historical Volatility 28.19%
  • IV Percentile 57%
  • IV Rank 28.57%
  • IV High 66.83% on 07/30/24
  • IV Low 34.01% on 11/26/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 600
  • Volume Avg (30-Day) 194
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 8,427
  • Open Int (30-Day) 7,156

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.91
  • Number of Estimates 10
  • High Estimate 1.08
  • Low Estimate 0.80
  • Prior Year 0.76
  • Growth Rate Est. (year over year) +19.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
235.75 +2.88%
on 12/19/24
259.27 -6.45%
on 12/11/24
+3.34 (+1.40%)
since 11/20/24
3-Month
185.13 +31.01%
on 09/25/24
259.27 -6.45%
on 12/11/24
+47.54 (+24.38%)
since 09/20/24
52-Week
148.00 +63.88%
on 07/31/24
277.34 -12.55%
on 02/16/24
-4.48 (-1.81%)
since 12/20/23

Most Recent Stories

More News
MYGN Stock Might Gain From the New Recognition of RiskScore Study

Myriad Genetics, Inc.’s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human Genetics....

MYGN : 13.36 (+1.44%)
PEN : 242.54 (-0.40%)
PAHC : 21.69 (-0.55%)
HAE : 75.44 (-1.90%)
3 Medical Instruments Industry Stocks to Buy on the GenAI Wave

Through 2024, advancements in AI and predictive analytics rapidly revolutionized the Medical Instruments industry, driving innovation in diagnostics, patient monitoring and personalized treatment. AI-powered...

VCYT : 40.89 (+4.66%)
PEN : 242.54 (-0.40%)
MASI : 169.52 (-0.28%)
Teleflex Expands CVC Portfolio in EMEA With New Launch: Stock to Gain?

Teleflex TFX recently launched its new Pressure Injectable Arrowg+ard Blue Plus MSB Procedure Kit in Europe, the Middle East and Africa (EMEA). This is regarded as a significant addition to the company’s...

TFX : 178.16 (+1.93%)
PEN : 242.54 (-0.40%)
PAHC : 21.69 (-0.55%)
HAE : 75.44 (-1.90%)
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?

Myriad Genetics, Inc.’s MYGN Prolaris prostate cancer prognostic test has been reinforced as an ‘Advanced Tool’ by the National Comprehensive Cancer Network (“NCCN”) in the fight against prostate...

MYGN : 13.36 (+1.44%)
PEN : 242.54 (-0.40%)
PAHC : 21.69 (-0.55%)
HAE : 75.44 (-1.90%)
CRL Stock to Gain From the Global Biotech Incubator Program Launch

Charles River Laboratories International, Inc. CRL has launched the Charles River Incubator Program (“CIP”) via its Global Innovation Center of Excellence (CoE). The initiative is designed to support...

PEN : 242.54 (-0.40%)
PAHC : 21.69 (-0.55%)
CRL : 185.77 (+1.99%)
HAE : 75.44 (-1.90%)
Insider Sale: EVP of $PEN (PEN) Sells 281 Shares

Johanna Roberts, the EVP of $PEN ($PEN), sold 281 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.4% of their shares. Following...

PEN : 242.54 (-0.40%)
Insider Sale: CEO and President of $PEN (PEN) Sells 3,281 Shares

Adam Elsesser, the CEO and President of $PEN ($PEN), sold 3,281 shares of the company on 11-20-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.4% of their...

PEN : 242.54 (-0.40%)
Implied Volatility Surging for Penumbra (PEN) Stock Options

Investors in Penumbra, Inc. PEN need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $310 Put had some of the highest implied volatility...

PEN : 242.54 (-0.40%)
Penumbra: Q3 Earnings Snapshot

Penumbra: Q3 Earnings Snapshot

PEN : 242.54 (-0.40%)
Why Penumbra Stock Zoomed 4% Higher Today

The latest news from the lab, plus an analyst's bullish move, combined to put some zip in the company's shares.

PEN : 242.54 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access...

See More

Key Turning Points

3rd Resistance Point 249.86
2nd Resistance Point 247.88
1st Resistance Point 245.21
Last Price 242.54
1st Support Level 240.55
2nd Support Level 238.57
3rd Support Level 235.90

See More

52-Week High 277.34
Last Price 242.54
Fibonacci 61.8% 227.93
Fibonacci 50% 212.67
Fibonacci 38.2% 197.41
52-Week Low 148.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar